ArriVent BioPharma (AVBP) Cash & Equivalents (2023 - 2026)

ArriVent BioPharma (AVBP) has 4 years of Cash & Equivalents data on file, last reported at $62.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 24.54% year-over-year to $62.1 million; the trailing twelve-month figure through Mar 2026 stood at $62.1 million (up 24.54% YoY), and the FY2025 full-year result was $45.5 million, down 38.7% from the prior year.
• Cash & Equivalents rose to $62.1 million in Q1 2026, from $45.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $317.4 million in Q1 2024 to a low of $45.5 million in Q4 2025.
• A 4-year average of $167.3 million and a median of $118.5 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents tumbled 84.29% in 2025 and grew 24.54% in 2026, its largest moves.
• Tracing AVBP's Cash & Equivalents over 4 years: stood at $124.3 million in 2023, then slumped by 40.23% to $74.3 million in 2024, then sank by 38.7% to $45.5 million in 2025, then soared by 36.37% to $62.1 million in 2026.
• Business Quant data shows AVBP's Cash & Equivalents at $62.1 million in Q1 2026, $45.5 million in Q4 2025, and $305.4 million in Q3 2025.